Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)
Status:
Unknown status
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This is a Single-center, Open-label, Single-arm,Non-randomized exploratory clinical trial
evaluating the efficacy and safety of Apatinib for third-line and later treatment of patients
with small cell lung cancer.